Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Rome – page 81

2 209 clinical trials in Rome, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Rome at a glance
2 209
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 209 trials in Rome

Open in trial search

Duchenne muscular dystrophy

Not yet recruiting

Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Intravenous sgt-003 in Ambulatory Male Patients with Duchenne Muscular Dystrophy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:SGT-003
  • Sponsor:Solid Biosciences Inc.

Infertility male

Not yet recruiting

Follitropin Alfa and Chorionic Gonadotrophin for Men with Male Infertility, Low Testosterone, and Low Sperm Count

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Follitropin Alfa
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Avelumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Infection prophylaxis

Not yet recruiting

Study of human normal immunoglobulin to prevent major infections in patients with hypogammaglobulinemia and autoimmune/rheumatic disease on B‑cell depletion therapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Neoplasm+2

Not yet recruiting

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Septic shock+1

Not yet recruiting

Angiotensin II in Children and Adolescents With Refractory Hypotension in Distributive Shock

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:ANGIOTENSIN II

Substance use disorder

Not yet recruiting

A study to evaluate the effects of rifaximin in patients with opioid use disorder

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Rifaximin
  • Sponsor:Fondazione Santa Lucia

Graft versus host disease

Not yet recruiting

A study to evaluate the effectiveness of MC0518 (mesenchymal stromal cells) in adults with acute graft-versus-host disease that has not responded to steroids and ruxolitinib

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mesenchymal Stromal Cells, Ex Vivo Cultured
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Autoimmune myositis

Not yet recruiting

A study to evaluate the safety and effectiveness of CABA-201, fludarabine, and cyclophosphamide in patients with active inflammatory myopathy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Caba-201
  • Sponsor:Cabaletta Bio Inc.

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Novartis Pharma AG

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ZAMPILIMAB
  • Sponsor:Chiesi Farmaceutici S.p.A.

Graft versus host disease

Not yet recruiting

Safety and Efficacy of MaaT013 with Vancomycin in Children and Adolescents with Gastrointestinal Acute Graft‑versus‑Host Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Vancomycin
  • Sponsor:Maat Pharma

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Rome

What the registry says about research in the country

01 Respiratory Diseases

Clinical studies focusing on Idiopathic Pulmonary Fibrosis and COPD, evaluating new therapeutic approaches for improving lung function and reducing disease progression.

  • Pulmonary function assessment
  • Disease exacerbation prevention
  • RSV prevention in high-risk populations

Advanced research includes novel antibody treatments and preventive measures for respiratory infections.

02 Oncology Research

Innovative trials targeting metastatic colorectal cancer, gastric cancer, and acute myeloid leukemia, exploring new treatment combinations and targeted therapies.

  • Targeted molecular therapies
  • Combination treatment approaches
  • Advanced stage cancer management

Studies focus on improving response rates and survival outcomes in various cancer types.

03 Neurological Conditions

Research into Parkinson's disease and acute ischemic stroke, investigating novel therapeutic approaches and neuroprotective strategies.

  • Early disease intervention
  • Stroke treatment optimization
  • Disease-modifying therapies

Studies aim to improve neurological outcomes and patient quality of life.

04 Immunological Disorders

Clinical trials examining Immune Thrombocytopenia and Hidradenitis Suppurativa, testing new therapeutic agents for immune-mediated conditions.

  • Immune system modulation
  • Novel biological therapies
  • Long-term disease management

Research focuses on improving treatment outcomes in challenging immune disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.